Edgewise Therapeutics (NASDAQ:EWTX) was downgraded to Sector Perform from prior Sector Outperform at Scotiabank after results ...

Across the study, two patients experienced “serious adverse events of atrial fibrillation (AF) requiring cardioversion,” ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: ...

Cytokinetics, Incorporated’s CYTK share price has surged by 13.20%, which has investors questioning if this is right time to ...

A number of myosin inhibitors are in development - some of these are skeletal, some of these are cardiac myosin inhibitors. One, Camzyos (mavacamten) from MyoKardia, now Bristol-Myers Squibb (BMY ...

In particular, their main value driver at this point seems to be Aficamten, which is a cardiac myosin inhibitor for HCM. And in that sense, they’ve also already made distribution agreements for ...

Atrial fibrillation has been seen with other cardiac myosin inhibitors, but the company said that the small number of cases in the trial group took away from one of EDG-7500's main benefits ...

an investigational orally administered first-in-class fast skeletal myosin inhibitor designed to protect against contraction-induced muscle damage, at the Muscular Dystrophy Association (MDA ...

As previously reported yesterday, Scotiabank downgraded Edgewise Therapeutics (EWTX) to Sector Perform from Outperform with a price target of ...

This is a disease where the heart muscle gets thicker, which can block blood flow and cause heart failure. The company revealed some good results from the study, but Scotiabank pointed out some ...